GlassScriptPhysician profile
Robyn Nicole Crisp
NPI 1144705922
$1,713.30
in general payments reported to CMS, 2019-2025
25 companies · $546 in 2025
The $546 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $458 · 2023: $523 · 2024: $186 · 2025: $546.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,255.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,255.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $266.57 | 2023-2024 | Trodelvy |
| Karyopharm Therapeutics INC. | $266.35 | 2022-2023 | Xpovio |
| Janssen Biotech, INC. | $150.68 | 2022-2025 | Carvykti, Rybrevant |
| Daiichi Sankyo INC. | $138.83 | 2024-2025 | Vanflyta |
| Bayer Healthcare Pharmaceuticals INC. | $109.36 | 2025 | |
| Secura Bio, INC. | $106.15 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $96.87 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $82.07 | 2022-2025 | Enhertu, Imfinzi |
| Ipsen Biopharmaceuticals, INC | $54.24 | 2024-2025 | Onivyde |
| Incyte Corporation | $47.09 | 2022 | |
| Genentech USA, INC. | $46.35 | 2025 | Venclexta, Polivy |
| Kyowa Kirin, INC. | $41.57 | 2024-2025 | Poteligeo |
| Novartis Pharmaceuticals Corporation | $39.69 | 2024-2025 | |
| Astellas Pharma US INC | $35.75 | 2023-2025 | Vyloy, Xospata |
| Pfizer INC. | $35.04 | 2022-2023 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Legend Biotech USA INC. | $33.25 | 2025 | Carvykti |
| Merck Sharp & Dohme LLC | $24.85 | 2025 | Keytruda, Welireg, Keytruda Qlex |
| Emd Serono, INC. | $24.01 | 2022 | |
| Syndax Pharmaceuticals, INC. | $22.75 | 2025 | Revuforj |
| Abbvie INC. | $18.17 | 2023 | |
| Amneal Pharmaceuticals LLC | $16.99 | 2023 | Avastin |
| Aveo Pharmaceuticals, INC. | $16.60 | 2022 | |
| Lilly USA, LLC | $15.17 | 2022 | |
| Mirati Therapeutics, INC. | $13.11 | 2023 | Krazati |
| Taiho Oncology, INC. | $11.79 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robyn Crisp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.